AIA
TEVA icon

AGF Investments America’s Teva Pharmaceuticals TEVA Stock Holding History

AGF Investments America’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-105,309
Closed -$844K – 70
2021
Q4 		$844K Buy
105,309
+2,506
+2% +$22.6K 0.16% 59
2021
Q3 		$1M Hold
102,803
– – 0.21% 60
2021
Q2 		$1.02M Buy
102,803
+2,187
+2% +$23.1K 0.24% 60
2021
Q1 		$1.16M Hold
100,616
– – 0.29% 61
2020
Q4 		$971K Buy
100,616
+94
+0.1% +$901 0.25% 64
2020
Q3 		$906K Buy
100,522
+1,219
+1% +$12.9K 0.27% 59
2020
Q2 		$1.22M Buy
99,303
+3,357
+3% +$38K 0.42% 51
2020
Q1 		$862K Buy
95,946
+1,370
+1% +$14K 0.36% 55
2019
Q4 		$927K Buy
94,576
+837
+0.9% +$7.47K 0.31% 53
2019
Q3 		$645K Buy
93,739
+1,842
+2% +$14.1K 0.21% 58
2019
Q2 		$848K Buy
91,897
+1,672
+2% +$20.2K 0.29% 55
2019
Q1 		$1.42M Buy
90,225
+29,904
+50% +$527K 0.5% 52
2018
Q4 		$930K Buy
60,321
+1,458
+2% +$29.9K 0.38% 56
2018
Q3 		$1.27M Buy
58,863
+19,361
+49% +$449K 0.44% 55
2018
Q2 		$961K Buy
39,502
+916
+2% +$18.7K 0.35% 59
2018
Q1 		$659K Buy
38,586
+707
+2% +$13.8K 0.25% 64
2017
Q4 		$718K Buy
37,879
+1,023
+3% +$15.4K 0.27% 62
2017
Q3 		$649K Buy
36,856
+454
+1% +$10.2K 0.25% 63
2017
Q2 		$1.21M Buy
36,402
+12,748
+54% +$395K 0.47% 56
2017
Q1 		$759K Buy
23,654
+425
+2% +$14.5K 0.31% 62
2016
Q4 		$842K Buy
23,229
+282
+1% +$11.3K 0.36% 62
2016
Q3 		$1.06M Buy
22,947
+82
+0.4% +$4.28K 0.46% 59
2016
Q2 		$1.15M Buy
+22,865
New +$1.22M 0.52% 57
2016
Q1 		– Sell
-9,179
Closed -$603K – 37
2015
Q4 		$603K Sell
9,179
-43,965
-83% -$2.72M 0.44% 33
2015
Q3 		$3M Sell
53,144
-4,077
-7% -$264K 1.9% 24
2015
Q2 		$3.38M Buy
57,221
+600
+1% +$37K 1.7% 27
2015
Q1 		$3.53M Sell
56,621
-3
-0% -$174 1.68% 28
2014
Q4 		$3.26M Sell
56,624
-77,491
-58% -$4.32M 1.63% 29
2014
Q3 		$7.21M Sell
134,115
-1,653
-1% -$87.6K 2.79% 17
2014
Q2 		$7.12M Sell
135,768
-12,300
-8% -$629K 2.76% 16
2014
Q1 		$7.82M Sell
148,068
-222,685
-60% -$10.3M 3.04% 16
2013
Q4 		$14.9M Sell
370,753
-5,600
-1% -$221K 5.14% 4
2013
Q3 		$14.2M Sell
376,353
-43,800
-10% -$1.71M 5.01% 5
2013
Q2 		$16.5M Buy
+420,153
New +$16.4M 5.74% 5

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

AGF Investments America's TEVA Position: Q1 2022 in Review

AGF Investments America sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 105,309 shares — an estimated $844K sold.

AGF Investments America first reported a position in TEVA in Q2 2013 and held it in 34 quarters. The position peaked at $16.5M in Q2 2013. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

  • AGF Investments America reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • AGF Investments America sold 105,309 Teva Pharmaceuticals shares in Q1 2022, an estimated $844K.
  • AGF Investments America first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 34 quarters.
  • AGF Investments America's Teva Pharmaceuticals position peaked at $16.5M in Q2 2013.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on AGF Investments America's 13F filing for Q1 2022, filed 10 May 2022.